Who makes Cyclosporine NOVA22007 0.1%?

Cyclosporine NOVA22007 0.1% is developed by Santen SAS.

What development phase is Cyclosporine NOVA22007 0.1% in?

Cyclosporine NOVA22007 0.1% is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Cyclosporine NOVA22007 0.1%

Santen SAS · Phase 2 active Small molecule

At a glance

Generic name	Cyclosporine NOVA22007 0.1%
Sponsor	Santen SAS
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC) (PHASE2, PHASE3)
NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye (PHASE2)
Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cyclosporine NOVA22007 0.1% CI brief — competitive landscape report
Cyclosporine NOVA22007 0.1% updates RSS · CI watch RSS
Santen SAS portfolio CI